Cellectis SA (NASDAQ:CLLS)’s share price traded down 2.4% during trading on Thursday . The company traded as low as $26.47 and last traded at $26.50, with a volume of 57,563 shares traded. The stock had previously closed at $27.14.

A number of equities analysts recently commented on the company. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Cellectis SA in a report on Tuesday, May 31st. Piper Jaffray Cos. reiterated a “buy” rating on shares of Cellectis SA in a report on Sunday, May 8th. Zacks Investment Research cut Cellectis SA from a “hold” rating to a “sell” rating in a report on Thursday, May 12th. Finally, Jefferies Group reiterated a “buy” rating on shares of Cellectis SA in a report on Friday, August 5th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $43.60.

The stock has a 50 day moving average of $26.53 and a 200 day moving average of $27.02. The company’s market capitalization is $912.41 million.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.